Skip to content

HedgeWeek-AIMA Mid-Year Allocator Sentiment Report 2025

This report, produced by Hedgeweek and sponsored by AlphaSense, summarises the surprising findings from a survey of nearly 100 global allocators in the first half of 2025. Despite geopolitical volatility, investors are displaying renewed optimism towards hedge funds.

The report highlights two key trends:

  1. Part I: Renewed Optimism
  2. Nearly half of the surveyed allocators plan to increase their hedge fund allocations.
  3. They are actively seeking new partnerships to capitalize on volatility and are raising their return expectations.
  4. The report details strategy preferences and regional shifts, particularly from institutions in APAC and the Middle East.
  5. Part II: Structural Shifts
  6. This section explores how allocators are viewing geopolitical tension as a strategic opportunity rather than a risk.
  7. It also examines changes in fee dynamics, the growing popularity of Separately Managed Accounts (SMAs), and other alternative investments.

The report includes an interview with Yashar Jedari from AlphaSense, who discusses how AI-powered research tools are enabling hedge fund managers to efficiently navigate this complex environment and level the playing field for smaller firms.

Explore more

APAC Macro Briefing 2026: Risk Meets Opportunity

In this report, we show how resources and workflows available in the AlphaSense platform can help contextualize the APAC macro environment, exploring the key implications for corporate leaders and investors across sectors.
Title slide for "APAC Macro Briefing 2026: Risk Meets Opportunity" with a map of the Asia-Pacific region.

Top AI Use Cases for Private Equity

In this report, discover how private equity teams are leveraging AI to accelerate conviction with speed. With purpose built, AI-driven solutions like AlphaSense, teams are gaining a competitive advantage with custom workflows and unmatched content sets for the most differentiated deal intelligence.
Top AI Use Cases For Private Equity by Barb Tague, Financial Research Leader. Illustration featuring isometric buildings and currency symbols.

AI in Drug Development 2026: From Experimentation to Execution

Learn how AI is reshaping drug development in real time, turning AI execution into a key competitive differentiator.
Presentation slide titled "AI in Drug Development 2026: From Experimentation to Execution" by Sara Mallatt and Sean Carmichael, with line art of laboratory equipment.

Transform intelligence
into advantage

Develop bold strategies, seize opportunities,
and lead with clarity and confidence.